HAEMATO AG (XTER:HAEK) 3-Year EBITDA Growth Rate : 52.80% (As of Jun. 2023)

View and export this data going back to 2005. Start your Free Trial

What is HAEMATO AG 3-Year EBITDA Growth Rate?

HAEMATO AG's EBITDA per Share for the six months ended in Jun. 2023 was €0.89.

During the past 12 months, HAEMATO AG's average EBITDA Per Share Growth Rate was 209.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 52.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of HAEMATO AG was 52.80% per year. The lowest was -55.90% per year. And the median was 3.20% per year.

Competitive Comparison of HAEMATO AG's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, HAEMATO AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HAEMATO AG's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HAEMATO AG's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where HAEMATO AG's 3-Year EBITDA Growth Rate falls into.

HAEMATO AG 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

HAEMATO AG (XTER:HAEK) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

HAEMATO AG 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of HAEMATO AG's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

HAEMATO AG (XTER:HAEK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HAEMATO AG (XTER:HAEK) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

HAEK:Germany HAEK:Germany HAEK:Germany

Address

Lilienthalstrasse 5c, Schonefeld, DEU, D-12529

Website

https://www.haemato.ag

HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG (XTER:HAEK) Headlines

No Headlines